

Simone Sredni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3216606/publications.pdf>

Version: 2024-02-01

35
papers

607
citations

759233

12
h-index

642732

23
g-index

37
all docs

37
docs citations

37
times ranked

887
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells. RSC Medicinal Chemistry, 2021, 12, 1910-1925.	3.9	1
2	Design, synthesis and evaluation of novel indole-2-carboxamides for growth inhibition of <i>Mycobacterium tuberculosis</i> and paediatric brain tumour cells. RSC Advances, 2021, 11, 15497-15511.	3.6	11
3	Polo-Like Kinase 4 (PLK4) Is Overexpressed in Central Nervous System Neuroblastoma (CNS-NB). Bioengineering, 2018, 5, 96.	3.5	20
4	ATRT-02. THE AURORA KINASE A (AURKA) INHIBITOR ALISERTIB ACTS SYNERGISTICALLY WITH A POLO-LIKE KINASE 4 (PLK4) INHIBITOR TO TARGET ATYPICAL TERATOID / RHABDOID TUMOR (AT/RT) CELLS. Neuro-Oncology, 2018, 20, i27-i27.	1.2	0
5	A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain. Pediatric Blood and Cancer, 2017, 64, e26551.	1.5	23
6	ATRT-04. A FUNCTIONAL SCREENING OF THE KINOME IDENTIFIES THE POLO-LIKE KINASE 4 (PLK4) AS A POTENTIAL THERAPEUTIC TARGET FOR ATYPICAL TERATOID/RHABDOID TUMORS (AT/RT), AND POSSIBLY, OTHER EMBRYONAL TUMORS OF THE BRAIN. Neuro-Oncology, 2017, 19, iv1-iv2.	1.2	0
7	The polo-like kinase 4 gene (PLK4) is overexpressed in pediatric medulloblastoma. Child's Nervous System, 2017, 33, 1031-1031.	1.1	11
8	Overexpression of TEAD4 in atypical teratoid/rhabdoid tumor: New insight to the pathophysiology of an aggressive brain tumor. Pediatric Blood and Cancer, 2017, 64, e26398.	1.5	9
9	Stabilization of HIF-1 α and HIF-2 α , up-regulation of MYC and accumulation of stabilized p53 constitute hallmarks of CNS-PNET animal model. PLoS ONE, 2017, 12, e0173106.	2.5	3
10	Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma. Oncotarget, 2017, 8, 111190-111212.	1.8	26
11	Spontaneous involution of pediatric low-grade gliomas: high expression of cannabinoid receptor 1 (CNR1) at the time of diagnosis may indicate involvement of the endocannabinoid system. Child's Nervous System, 2016, 32, 2061-2067.	1.1	28
12	Extensive miRNA expression analysis in craniopharyngiomas. Child's Nervous System, 2016, 32, 1617-1624.	1.1	11
13	Using CRISPR/Cas9 to explore the human kinome: A tool to identify new potential therapeutic targets for malignant rhabdoid tumors (MRT).. Journal of Clinical Oncology, 2016, 34, 10544-10544.	1.6	0
14	A Mouse Model of Human Primitive Neuroectodermal Tumors Resulting from Microenvironmentally-Driven Malignant Transformation of Orthotopically Transplanted Radial Glial Cells. PLoS ONE, 2015, 10, e0121707.	2.5	6
15	Atypical teratoid rhabdoid tumors of the posterior fossa in children. Child's Nervous System, 2015, 31, 1717-1728.	1.1	13
16	Activation of ErbB2- ErbB3 signaling pathway supports potential therapeutic activity of ErbB inhibitors in AT/RT. Journal of Neuro-Oncology, 2014, 118, 201-203.	2.9	7
17	Histone deacetylases expression in atypical teratoid rhabdoid tumors. Child's Nervous System, 2013, 29, 5-9.	1.1	13
18	Methylation alterations of WT1 and homeobox genes in inflamed muscle biopsy samples from patients with untreated juvenile dermatomyositis suggest self-renewal capacity. Arthritis and Rheumatism, 2012, 64, 3478-3485.	6.7	27

#	ARTICLE	IF	CITATIONS
19	MicroRNA expression profiling for Molecular Classification of pediatric brain tumors. <i>Pediatric Blood and Cancer</i> , 2011, 57, 183-184.	1.5	15
20	Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets. <i>Child's Nervous System</i> , 2010, 26, 279-283.	1.1	28
21	Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets. <i>Laboratory Investigation</i> , 2010, 90, 724-738.	3.7	89
22	Childhood carcinoid tumors: description of a case series in a Brazilian cancer center. <i>Sao Paulo Medical Journal</i> , 2006, 124, 21-25.	0.9	31
23	Hyperplastic perilobar nephroblastomatosis: Long-term survival of 52 patients. <i>Pediatric Blood and Cancer</i> , 2006, 46, 203-221.	1.5	86
24	Hepatoblastomas and Liver Development: A Study of Cytokeratin Immunoexpression in Twenty-Nine Hepatoblastomas. <i>Pediatric and Developmental Pathology</i> , 2006, 9, 196-202.	1.0	26
25	Pan-cytokeratin immunoexpression in Wilms' tumors: a simple approach for understanding tumor epithelial differentiation. <i>Sao Paulo Medical Journal</i> , 2004, 122, 181-183.	0.9	3
26	Endodermal Sinus Tumor of the Parotid Gland in a Child. <i>Pediatric and Developmental Pathology</i> , 2004, 7, 77-80.	1.0	10
27	Letter to the Editor. <i>Pediatric and Developmental Pathology</i> , 2004, 7, 668-669.	1.0	4
28	CORRESPONDENCE RE: CARPENTIERI DF, NICHOLS K, CHOU PM, MATHEWS M, PAWEL B, HUFF D. THE EXPRESSION OF WT1 IN THE DIFFERENTIATION OF RHABDOMYOSARCOMA FROM OTHER PEDIATRIC SMALL ROUND BLUE CELL TUMORS. <i>MOD PATHOL</i> 2002;15(10):1080-6.. <i>Modern Pathology</i> , 2003, 16, 1178-1179.	5.5	7
29	Immunohistochemical detection of p53 protein expression as a prognostic indicator in Wilms tumor. <i>Medical and Pediatric Oncology</i> , 2001, 37, 455-458.	1.0	37
30	Correspondence Re: Lack EE, Askin FB, Dehner LB, Page DL, Weiss LM. Recommendations for Reporting of Tumors of the Adrenal Cortex and Medulla. <i>Mod Pathol</i> 1999;12:835-9.. <i>Modern Pathology</i> , 2000, 13, 920-920.	5.5	1
31	Head and neck teratoma in a neonate. , 1999, 32, 232-233.		3
32	Endodermal sinus tumor of the vagina in children. , 1999, 32, 377-381.		24
33	Primitive neuroectodermal tumor (PNET)/extraosseous Ewing sarcoma of the kidney. , 1998, 30, 303-307.		15
34	Association of gastrointestinal stromal tumor (leiomyosarcoma), pulmonary chondroma, and nonfunctional retroperitoneal paraganglioma. , 1998, 31, 537-540.		9
35	Abdominal Recurrence of Osteogenic Sarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 1998, 20, 271-273.	0.6	7